Development of vaccines for Chagas disease (CRUZIVAX): stakeholders’ preferences and potential impacts on healthcare

Autores
Ramponi, Francesco; Aerts, Céline; Sartor, Paula; Pinazo, María Jesús; Freilij, Héctor; Guzmán, Carlos A.; Malchiodi, Emilio Luis; Sicuri, Elisa
Año de publicación
2023
Idioma
español castellano
Tipo de recurso
artículo
Estado
versión publicada
Descripción
A vaccine for Chagas disease does not currently exist. This study aims to inform the development of two vaccines for the prevention and treatment of Trypanosoma cruzi infection, and guide their pre-clinical phase up to clinical phase I. The three main objectives are: 1) to explore patients’ and policy makers’ preferences on the candidate vaccines in Argentina and Spain; 2) to investigate health-related quality of life of patients affected by Chagas disease; and 3) to assess the potential health provider savings associated with the vaccines, in terms of resource use and health care costs. Discrete choice experiments will be employed to estimate and characterize the theoretical demand for the vaccines and investigate patients’ and policy makers’ preferences. Health-related quality of life will be assessed using the EQ-5D-3L questionnaire. Resources use and costs associated with Chagas disease will be investigated using information from the databases of the Hospital Clínic of Barcelona.
Fil: Ramponi, Francesco. Instituto de Salud Global de Barcelona; España
Fil: Aerts, Céline. Instituto de Salud Global de Barcelona; España
Fil: Sartor, Paula. Gobierno de la Provincia de Chaco. Ministerio de Salud Publica; Argentina. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas y Naturales y Agrimensura; Argentina
Fil: Pinazo, María Jesús. Instituto de Salud Global de Barcelona; España
Fil: Freilij, Héctor. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutiérrez"; Argentina
Fil: Guzmán, Carlos A.. Helmholtz Centre For Infection Research ; Alemania
Fil: Malchiodi, Emilio Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones en Microbiología y Parasitología Médica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones en Microbiología y Parasitología Médica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
Fil: Sicuri, Elisa. The London School of Economics and Political Science; Reino Unido. Instituto de Salud Global de Barcelona; España
Materia
ARGENTINA
CHAGAS DISEASE
HEALTH CARE COSTS
PATIENT PREFERENCES
QUALITY OF LIFE
SPAIN
SURVEYS AND QUESTIONNAIRES
TRYPANOSOMA CRUZI
VACCINES
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/227827
Acceder
id CONICETDig_bf8e1a89fce74b4370f3489cee15a747
oai_identifier_str oai:ri.conicet.gov.ar:11336/227827
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Development of vaccines for Chagas disease (CRUZIVAX): stakeholders’ preferences and potential impacts on healthcareDesarrollo de vacunas para la enfermedad de Chagas (CRUZIVAX): preferencias de las partes interesadas y posibles impactos en la asistencia sanitariaRamponi, FrancescoAerts, CélineSartor, PaulaPinazo, María JesúsFreilij, HéctorGuzmán, Carlos A.Malchiodi, Emilio LuisSicuri, ElisaARGENTINACHAGAS DISEASEHEALTH CARE COSTSPATIENT PREFERENCESQUALITY OF LIFESPAINSURVEYS AND QUESTIONNAIRESTRYPANOSOMA CRUZIVACCINEShttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3A vaccine for Chagas disease does not currently exist. This study aims to inform the development of two vaccines for the prevention and treatment of Trypanosoma cruzi infection, and guide their pre-clinical phase up to clinical phase I. The three main objectives are: 1) to explore patients’ and policy makers’ preferences on the candidate vaccines in Argentina and Spain; 2) to investigate health-related quality of life of patients affected by Chagas disease; and 3) to assess the potential health provider savings associated with the vaccines, in terms of resource use and health care costs. Discrete choice experiments will be employed to estimate and characterize the theoretical demand for the vaccines and investigate patients’ and policy makers’ preferences. Health-related quality of life will be assessed using the EQ-5D-3L questionnaire. Resources use and costs associated with Chagas disease will be investigated using information from the databases of the Hospital Clínic of Barcelona.Fil: Ramponi, Francesco. Instituto de Salud Global de Barcelona; EspañaFil: Aerts, Céline. Instituto de Salud Global de Barcelona; EspañaFil: Sartor, Paula. Gobierno de la Provincia de Chaco. Ministerio de Salud Publica; Argentina. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas y Naturales y Agrimensura; ArgentinaFil: Pinazo, María Jesús. Instituto de Salud Global de Barcelona; EspañaFil: Freilij, Héctor. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutiérrez"; ArgentinaFil: Guzmán, Carlos A.. Helmholtz Centre For Infection Research ; AlemaniaFil: Malchiodi, Emilio Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones en Microbiología y Parasitología Médica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones en Microbiología y Parasitología Médica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; ArgentinaFil: Sicuri, Elisa. The London School of Economics and Political Science; Reino Unido. Instituto de Salud Global de Barcelona; EspañaElsevier2023-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/227827Ramponi, Francesco; Aerts, Céline; Sartor, Paula; Pinazo, María Jesús; Freilij, Héctor; et al.; Development of vaccines for Chagas disease (CRUZIVAX): stakeholders’ preferences and potential impacts on healthcare; Elsevier; Gaceta Sanitaria; 37; 1-2023; 1-40213-9111CONICET DigitalCONICETspainfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0213911122001716info:eu-repo/semantics/altIdentifier/doi/10.1016/j.gaceta.2022.102275info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2026-08-25T14:33:47Zoai:ri.conicet.gov.ar:11336/227827instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982026-08-25 14:33:48.029CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Development of vaccines for Chagas disease (CRUZIVAX): stakeholders’ preferences and potential impacts on healthcare
Desarrollo de vacunas para la enfermedad de Chagas (CRUZIVAX): preferencias de las partes interesadas y posibles impactos en la asistencia sanitaria
title Development of vaccines for Chagas disease (CRUZIVAX): stakeholders’ preferences and potential impacts on healthcare
spellingShingle Development of vaccines for Chagas disease (CRUZIVAX): stakeholders’ preferences and potential impacts on healthcare
Ramponi, Francesco
ARGENTINA
CHAGAS DISEASE
HEALTH CARE COSTS
PATIENT PREFERENCES
QUALITY OF LIFE
SPAIN
SURVEYS AND QUESTIONNAIRES
TRYPANOSOMA CRUZI
VACCINES
title_short Development of vaccines for Chagas disease (CRUZIVAX): stakeholders’ preferences and potential impacts on healthcare
title_full Development of vaccines for Chagas disease (CRUZIVAX): stakeholders’ preferences and potential impacts on healthcare
title_fullStr Development of vaccines for Chagas disease (CRUZIVAX): stakeholders’ preferences and potential impacts on healthcare
title_full_unstemmed Development of vaccines for Chagas disease (CRUZIVAX): stakeholders’ preferences and potential impacts on healthcare
title_sort Development of vaccines for Chagas disease (CRUZIVAX): stakeholders’ preferences and potential impacts on healthcare
dc.creator.none.fl_str_mv Ramponi, Francesco
Aerts, Céline
Sartor, Paula
Pinazo, María Jesús
Freilij, Héctor
Guzmán, Carlos A.
Malchiodi, Emilio Luis
Sicuri, Elisa
author Ramponi, Francesco
author_facet Ramponi, Francesco
Aerts, Céline
Sartor, Paula
Pinazo, María Jesús
Freilij, Héctor
Guzmán, Carlos A.
Malchiodi, Emilio Luis
Sicuri, Elisa
author_role author
author2 Aerts, Céline
Sartor, Paula
Pinazo, María Jesús
Freilij, Héctor
Guzmán, Carlos A.
Malchiodi, Emilio Luis
Sicuri, Elisa
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv ARGENTINA
CHAGAS DISEASE
HEALTH CARE COSTS
PATIENT PREFERENCES
QUALITY OF LIFE
SPAIN
SURVEYS AND QUESTIONNAIRES
TRYPANOSOMA CRUZI
VACCINES
topic ARGENTINA
CHAGAS DISEASE
HEALTH CARE COSTS
PATIENT PREFERENCES
QUALITY OF LIFE
SPAIN
SURVEYS AND QUESTIONNAIRES
TRYPANOSOMA CRUZI
VACCINES
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv A vaccine for Chagas disease does not currently exist. This study aims to inform the development of two vaccines for the prevention and treatment of Trypanosoma cruzi infection, and guide their pre-clinical phase up to clinical phase I. The three main objectives are: 1) to explore patients’ and policy makers’ preferences on the candidate vaccines in Argentina and Spain; 2) to investigate health-related quality of life of patients affected by Chagas disease; and 3) to assess the potential health provider savings associated with the vaccines, in terms of resource use and health care costs. Discrete choice experiments will be employed to estimate and characterize the theoretical demand for the vaccines and investigate patients’ and policy makers’ preferences. Health-related quality of life will be assessed using the EQ-5D-3L questionnaire. Resources use and costs associated with Chagas disease will be investigated using information from the databases of the Hospital Clínic of Barcelona.
Fil: Ramponi, Francesco. Instituto de Salud Global de Barcelona; España
Fil: Aerts, Céline. Instituto de Salud Global de Barcelona; España
Fil: Sartor, Paula. Gobierno de la Provincia de Chaco. Ministerio de Salud Publica; Argentina. Universidad Nacional del Nordeste. Facultad de Ciencias Exactas y Naturales y Agrimensura; Argentina
Fil: Pinazo, María Jesús. Instituto de Salud Global de Barcelona; España
Fil: Freilij, Héctor. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutiérrez"; Argentina
Fil: Guzmán, Carlos A.. Helmholtz Centre For Infection Research ; Alemania
Fil: Malchiodi, Emilio Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones en Microbiología y Parasitología Médica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones en Microbiología y Parasitología Médica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
Fil: Sicuri, Elisa. The London School of Economics and Political Science; Reino Unido. Instituto de Salud Global de Barcelona; España
description A vaccine for Chagas disease does not currently exist. This study aims to inform the development of two vaccines for the prevention and treatment of Trypanosoma cruzi infection, and guide their pre-clinical phase up to clinical phase I. The three main objectives are: 1) to explore patients’ and policy makers’ preferences on the candidate vaccines in Argentina and Spain; 2) to investigate health-related quality of life of patients affected by Chagas disease; and 3) to assess the potential health provider savings associated with the vaccines, in terms of resource use and health care costs. Discrete choice experiments will be employed to estimate and characterize the theoretical demand for the vaccines and investigate patients’ and policy makers’ preferences. Health-related quality of life will be assessed using the EQ-5D-3L questionnaire. Resources use and costs associated with Chagas disease will be investigated using information from the databases of the Hospital Clínic of Barcelona.
publishDate 2023
dc.date.none.fl_str_mv 2023-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/227827
Ramponi, Francesco; Aerts, Céline; Sartor, Paula; Pinazo, María Jesús; Freilij, Héctor; et al.; Development of vaccines for Chagas disease (CRUZIVAX): stakeholders’ preferences and potential impacts on healthcare; Elsevier; Gaceta Sanitaria; 37; 1-2023; 1-4
0213-9111
CONICET Digital
CONICET
url http://hdl.handle.net/11336/227827
identifier_str_mv Ramponi, Francesco; Aerts, Céline; Sartor, Paula; Pinazo, María Jesús; Freilij, Héctor; et al.; Development of vaccines for Chagas disease (CRUZIVAX): stakeholders’ preferences and potential impacts on healthcare; Elsevier; Gaceta Sanitaria; 37; 1-2023; 1-4
0213-9111
CONICET Digital
CONICET
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0213911122001716
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.gaceta.2022.102275
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1874774180154572800
score 13.265058

Publicaciones similares